159 related articles for article (PubMed ID: 16636898)
1. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
Popik P; Krawczyk M; Golembiowska K; Nowak G; Janowsky A; Skolnick P; Lippa A; Basile AS
Cell Mol Neurobiol; 2006; 26(4-6):857-73. PubMed ID: 16636898
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
3. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
5. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
6. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Golembiowska K; Kowalska M; Bymaster FP
Synapse; 2012 May; 66(5):435-44. PubMed ID: 22213370
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
8. Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.
Yang AR; Yi HS; Warnock KT; Mamczarz J; June HL; Mallick N; Krieter PA; Tonelli L; Skolnick P; Basile AS; June HL
Alcohol Clin Exp Res; 2012 May; 36(5):863-73. PubMed ID: 22150508
[TBL] [Abstract][Full Text] [Related]
9. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.
Tizzano JP; Stribling DS; Perez-Tilve D; Strack A; Frassetto A; Chen RZ; Fong TM; Shearman L; Krieter PA; Tschöp MH; Skolnick P; Basile AS
J Pharmacol Exp Ther; 2008 Mar; 324(3):1111-26. PubMed ID: 18089843
[TBL] [Abstract][Full Text] [Related]
10. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.
McMillen BA; Shank JE; Jordan KB; Williams HL; Basile AS
Alcohol Clin Exp Res; 2007 Nov; 31(11):1866-71. PubMed ID: 17908267
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide increases degradation of central monoamines: an in vivo microdialysis study in the nucleus accumbens and medial prefrontal cortex of mice.
van Heesch F; Prins J; Konsman JP; Korte-Bouws GA; Westphal KG; Rybka J; Olivier B; Kraneveld AD; Korte SM
Eur J Pharmacol; 2014 Feb; 725():55-63. PubMed ID: 24444442
[TBL] [Abstract][Full Text] [Related]
12. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Prins J; Denys DA; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Groenink L; Olivier B; Korte SM
Eur J Pharmacol; 2010 May; 633(1-3):55-61. PubMed ID: 20153745
[TBL] [Abstract][Full Text] [Related]
13. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
14. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
15. The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats.
Prins J; Kenny PJ; Doomernik I; Schreiber R; Olivier B; Mechiel Korte S
Eur J Pharmacol; 2012 Oct; 693(1-3):51-6. PubMed ID: 23010469
[TBL] [Abstract][Full Text] [Related]
16. The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake.
Viana A; do Rego JC; von Poser G; Ferraz A; Heckler AP; Costentin J; Kuze Rates SM
Neuropharmacology; 2005 Dec; 49(7):1042-52. PubMed ID: 16040063
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
[TBL] [Abstract][Full Text] [Related]
18. Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats.
Umehara M; Ago Y; Fujita K; Hiramatsu N; Takuma K; Matsuda T
Eur J Pharmacol; 2013 Feb; 702(1-3):250-7. PubMed ID: 23376565
[TBL] [Abstract][Full Text] [Related]
19. "Broad spectrum" antidepressants: is more better for the treatment of depression?
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Life Sci; 2003 Nov; 73(25):3175-9. PubMed ID: 14561522
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.
Basile AS; Janowsky A; Golembiowska K; Kowalska M; Tam E; Benveniste M; Popik P; Nikiforuk A; Krawczyk M; Nowak G; Krieter PA; Lippa AS; Skolnick P; Koustova E
J Pharmacol Exp Ther; 2007 Jun; 321(3):1208-25. PubMed ID: 17325229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
